After 9 Meters Biopharma announced the design of its Phase 3 clinical trial of vurolenatide for adults with short bowel syndrome, Brookline analyst Kumaraguru Raja said the trial design increases the odds of success given that hitting either of its endpoints can support an NDA filing. Raja reiterates a Buy rating and $74 price target on 9 Meters shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NMTR: